Axovant Gene Therapies Ltd (NASDAQ:AXGT) Forecasted to Earn FY2024 Earnings of ($1.52) Per Share

Axovant Gene Therapies Ltd (NASDAQ:AXGT) – Research analysts at Oppenheimer issued their FY2024 earnings estimates for Axovant Gene Therapies in a report released on Wednesday, June 12th. Oppenheimer analyst J. Olson forecasts that the company will post earnings per share of ($1.52) for the year.

Other analysts have also issued research reports about the stock. Chardan Capital upgraded shares of Axovant Gene Therapies from a “neutral” rating to a “buy” rating and set a $32.00 target price on the stock in a research report on Monday, March 11th. Guggenheim began coverage on shares of Axovant Gene Therapies in a research note on Friday, February 15th. They set a “buy” rating and a $56.00 target price on the stock. Zacks Investment Research raised shares of Axovant Gene Therapies from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Wednesday, April 10th. HC Wainwright reissued a “buy” rating and issued a $56.00 price target on shares of Axovant Gene Therapies in a research note on Tuesday, March 12th. Finally, Cowen reaffirmed a “hold” rating on shares of Axovant Gene Therapies in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Axovant Gene Therapies currently has an average rating of “Buy” and an average target price of $36.20.

AXGT opened at $4.85 on Friday. Axovant Gene Therapies has a fifty-two week low of $3.81 and a fifty-two week high of $33.12. The firm has a market capitalization of $95.22 million, a price-to-earnings ratio of -0.60 and a beta of 1.39. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.63 and a quick ratio of 2.02.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its quarterly earnings results on Tuesday, June 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.70) by $1.25.

A number of hedge funds and other institutional investors have recently modified their holdings of AXGT. Marshall Wace LLP purchased a new stake in Axovant Gene Therapies in the 1st quarter worth about $272,000. Jane Street Group LLC purchased a new stake in Axovant Gene Therapies in the 1st quarter worth about $48,000. Morgan Stanley purchased a new stake in Axovant Gene Therapies in the 1st quarter worth about $291,000. Macquarie Group Ltd. purchased a new stake in Axovant Gene Therapies in the 1st quarter worth about $1,150,000. Finally, Jefferies Group LLC purchased a new stake in Axovant Gene Therapies in the 1st quarter worth about $3,354,000.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Recommended Story: Portfolio Manager

Earnings History and Estimates for Axovant Gene Therapies (NASDAQ:AXGT)

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply